Suppr超能文献

β-内酰胺抗生素的作用靶点与耐药机制:从共价抑制剂到底物

β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates.

作者信息

Mora-Ochomogo Montserrat, Lohans Christopher T

机构信息

Department of Biomedical and Molecular Sciences, Queen's University Kingston ON K7L 3N6 Canada

出版信息

RSC Med Chem. 2021 Aug 4;12(10):1623-1639. doi: 10.1039/d1md00200g. eCollection 2021 Oct 20.

Abstract

The β-lactams are the most widely used antibacterial agents worldwide. These antibiotics, a group that includes the penicillins and cephalosporins, are covalent inhibitors that target bacterial penicillin-binding proteins and disrupt peptidoglycan synthesis. Bacteria can achieve resistance to β-lactams in several ways, including the production of serine β-lactamase enzymes. While β-lactams also covalently interact with serine β-lactamases, these enzymes are capable of deacylating this complex, treating the antibiotic as a substrate. In this tutorial-style review, we provide an overview of the β-lactam antibiotics, focusing on their covalent interactions with their target proteins and resistance mechanisms. We begin by describing the structurally diverse range of β-lactam antibiotics and β-lactamase inhibitors that are currently used as therapeutics. Then, we introduce the penicillin-binding proteins, describing their functions and structures, and highlighting their interactions with β-lactam antibiotics. We next describe the classes of serine β-lactamases, exploring some of the mechanisms by which they achieve the ability to degrade β-lactams. Finally, we introduce the l,d-transpeptidases, a group of bacterial enzymes involved in peptidoglycan synthesis which are also targeted by β-lactam antibiotics. Although resistance mechanisms are now prevalent for all antibiotics in this class, past successes in antibiotic development have at least delayed this onset of resistance. The β-lactams continue to be an essential tool for the treatment of infectious disease, and recent advances (, β-lactamase inhibitor development) will continue to support their future use.

摘要

β-内酰胺类是全球使用最广泛的抗菌药物。这些抗生素包括青霉素类和头孢菌素类,它们是共价抑制剂,作用于细菌青霉素结合蛋白,破坏肽聚糖合成。细菌可通过多种方式对β-内酰胺类产生耐药性,包括产生丝氨酸β-内酰胺酶。虽然β-内酰胺类也与丝氨酸β-内酰胺酶发生共价相互作用,但这些酶能够使该复合物脱酰基,将抗生素当作底物进行处理。在本教程式综述中,我们概述了β-内酰胺类抗生素,重点介绍它们与靶蛋白的共价相互作用及耐药机制。我们首先描述目前用作治疗药物的结构多样的β-内酰胺类抗生素和β-内酰胺酶抑制剂。然后,我们介绍青霉素结合蛋白,描述其功能和结构,并强调它们与β-内酰胺类抗生素的相互作用。接下来,我们描述丝氨酸β-内酰胺酶的类别,探讨它们实现降解β-内酰胺能力的一些机制。最后,我们介绍L,D-转肽酶,这是一组参与肽聚糖合成的细菌酶,也是β-内酰胺类抗生素的作用靶点。尽管目前这类抗生素的所有耐药机制都很普遍,但过去抗生素研发的成功至少延缓了耐药性的出现。β-内酰胺类仍然是治疗传染病的重要工具,最近的进展(如β-内酰胺酶抑制剂的研发)将继续支持它们未来的使用。

相似文献

2
Drug Discovery in the Field of β-Lactams: An Academic Perspective.β-内酰胺类药物研发:学术视角
Antibiotics (Basel). 2024 Jan 8;13(1):59. doi: 10.3390/antibiotics13010059.
7
β-lactam antibiotics: An overview from a medicinal chemistry perspective.β-内酰胺类抗生素:从药物化学角度综述。
Eur J Med Chem. 2020 Dec 15;208:112829. doi: 10.1016/j.ejmech.2020.112829. Epub 2020 Sep 16.
8
Class D β-lactamases: a reappraisal after five decades.D 类 β-内酰胺酶:五十年后的再评价。
Acc Chem Res. 2013 Nov 19;46(11):2407-15. doi: 10.1021/ar300327a. Epub 2013 Jul 31.
10
Beta-lactamases and beta-lactamase inhibitors.β-内酰胺酶与β-内酰胺酶抑制剂
Int J Antimicrob Agents. 1999 Aug;12 Suppl 1:S3-7; discussion S26-7. doi: 10.1016/s0924-8579(99)00085-0.

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验